Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Treatment of hot flashes with low-dose risperidone
ISRCTN ISRCTN05964399
ClinicalTrials.gov identifier
Public title Treatment of hot flashes with low-dose risperidone
Scientific title Treatment of hot flashes with low-dose risperidone: An uncontrolled pilot study
Acronym N/A
Serial number at source KTCT-P2a
Study hypothesis By chance, risperidone was reported to have an effect on remission of hot flashes. We postulate that risperidone could sereve as a potential drug to treat hot flashes.
Lay summary
Ethics approval The Research Ethics Committee of Kuang-Tein General Hospital approved on the 20th of March 2005 (ref: KTCTP2a)
Study design Pilot prospective non-randomised uncontrolled trial
Countries of recruitment Taiwan
Disease/condition/study domain Hot flashes
Participants - inclusion criteria Menopausal (perimenopausal or postmenopausal) women with at least a moderate severity (i.e., ≥ 2 on a 0–4 scale) of hot flashes
Participants - exclusion criteria 1. Menopausal women who take antipsychotic drug or/and antidepressants
2. Menopausal women who have breast cancer
Anticipated start date 01/06/2005
Anticipated end date 31/05/2006
Status of trial Completed
Patient information material Not available in web format, please use contact details below to request a patient information sheet
Target number of participants 6
Interventions Patients complete hot flash diaries regarding the frequency and severity of hot flashes everyday in a one-week baseline period, in the 3-month risperidone treatment period, and during the first two weeks after total risperidone withdrawal.
Primary outcome measure(s) The efficacy of risperidone for hot flashes is assessed by the average number of hot flashes per day, and the average daily hot-flash score (frequency × severity)
Secondary outcome measure(s) None
Sources of funding Kuang-Tien General Hospital (Taiwan) - investigator led study
Trial website
Publications
Contact name Dr  Hung-Ming  Wu
  Address 135 Nanxiao St.
Changhua City
  City/town Changhua
  Zip/Postcode 500
  Country Taiwan
Sponsor Kuang-Tien General Hospital (Taiwan)
  Address 135 Nanxiao St.
Changhua City
  City/town Changhua
  Zip/Postcode 500
  Country Taiwan
Date applied 23/06/2010
Last edited 08/07/2010
Date ISRCTN assigned 08/07/2010
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central